A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis

Inclusion Criteria: * Adult patients, 18 to 65 years of age inclusive * Chronic hepatitis C, genotype 1 or 4 * Cohort 1: Treatment-naïve for hepatitis C * Cohort 2: Prior null responder to treatment with approved doses of pegylated interferon plus ribavirin * Liver biopsy confirming cirrhosis * Compensated cirrhosis (Child-Pugh A) Exclusion Criteria: * Pregnant or lactating women or male partners of women who are pregnant * History or presence of decompensated liver disease (ascites, hepatic encephalopathy, hepatocellular carcinoma, or bleeding esophageal varices) * Cohort 2: Patients who discontinued previous pegylated interferon plus ribavirin treatment due to reasons other than null response * History of clinically significant cardiovascular or cerebrovascular disease